General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Eli Lilly and Company(MODEST) RESEARCH/RESEARCH GRANTS: Kaneka, Inc (SIGNIFICANT) OTHER FINANCIAL BENEFIT: Novartis Corporation(NONE)

View Full Disclosure